Vol. 10 (2025): Proceedings of the 2nd International Conference on Business, Management and Sustainability (ICBMS 2025)
E-ISSN: 3105-0522 P-ISSN：3105-0514
DOI: https://doi.org/10.70267/icbms.2502.247252

Valuation Analysis of Mindray Medical's Acquisition of Huitai Medical

Liang Jin*

Surrey International College, Dongbei University of Finance and Economics, Dalian, 116000, China

**Corresponding author: Liang Jin*

Abstract

This study examines the 2024 acquisition of Huitai Medical by Mindray Medical for CNY 6.65 billion, with particular focus on assessing the reasonableness of the acquisition premium. The analysis begins with an overview of the two companies: Mindray Medical, a leading medical device manufacturer with 2023 revenues exceeding CNY 40 billion, and Huitai Medical, a competitive electrophysiology sector player generating CNY 1.65 billion in revenue in 2023. Historical financial data for Huitai Medical covering 2023-2024 are examined to establish baseline performance metrics. The valuation methodology employs a Discounted Cash Flow (DCF) framework, projecting Huitai's revenue growth, net income, and Free Cash Flow to the Firm (FCFF) through 2030 and into the terminal period. Utilizing a Weighted Average Cost of Capital (WACC) of 8.21% as the discount rate and incorporating a perpetual growth assumption for the terminal value, the analysis yields an enterprise value of CNY 28.918 billion. After adjusting for net debt, the equity value is estimated at CNY 29.938 billion, corresponding to an intrinsic value of approximately CNY 309.55 per share. Sensitivity analysis establishes a valuation range of CNY 262-361 per share under varying assumptions. The study concludes that the 25% acquisition premium is justified, primarily attributable to substantial anticipated synergies and Mindray's strong financial capacity to absorb the transaction costs. However, several risk factors warrant attention, including potential underperformance in domestic market substitution strategies. Ultimately, the acquisition's success will depend critically on effective post-merger integration and the sustained operational development of the combined entity.

Keywords

mergers and acquisitions, valuation analysis, intrinsic valuation model

1. Introduction

Valuation analysis is fundamental to mergers and acquisitions (M&A). As markets become increasingly competitive, M&A has emerged as a critical mechanism through which firms achieve rapid expansion, strengthen market positioning, and optimize resource allocation. While industry-specific metrics such as price-to-book ratios provide useful benchmarks in certain contexts, horizontal acquisitions do not uniformly enhance firm value (Yang, 2023). Integrating absolute and relative valuation approaches enables more comprehensive assessment of M&A effectiveness and better accounts for synergistic effects (Zhang, 2021). Nevertheless, acquisitions remain vulnerable to valuation risk; income-based approaches relying on single methods lack robustness, requiring firms to rigorously satisfy the underlying assumptions of their chosen framework (Ren, 2020). The standard DCF methodology involves projecting annual free cash flows, determining an appropriate discount rate, and applying a perpetual growth model to estimate terminal value (Yang, 2015). Given the

inherent complexity of M&A transactions and their sensitivity to execution quality at each stage, traditional valuation methods often inadequately capture significant uncertainties. This has prompted the development of real options frameworks that explicitly incorporate the value of managerial flexibility in investment timing and structure (Cao, 2015). Consequently, valuation outcomes are contingent upon methodological choices and can only be definitively assessed ex post, underscoring the necessity of rigorous analytical frameworks.

This paper investigate Mindray Medical's 2024 acquisition of Huitai Medical, focusing on target valuation and transaction pricing. We construct a DCF model utilizing two years of historical financial data, project future free cash flows, discount them to present value, and conduct sensitivity analysis to validate our findings.

2. Case Background

Founded in 1991 as a medical device distributor, Mindray Medical has evolved into China's leading comprehensive medical equipment manufacturer, operating three core business segments: life information and support, in-vitro diagnostics, and medical imaging. Headquartered in Shenzhen, the company maintains R&D centers in Shenzhen, Beijing, and Seattle. In September 2006, Mindray became the first Chinese medical equipment firm listed on the New York Stock Exchange; that October, it received approval from the Ministry of Science and Technology to establish the National Medical Diagnostic Instrument Engineering Technology Research Center. The company operates 44 overseas subsidiaries across more than 30 countries, supported by an extensive global distribution and service network. In 2023, Mindray generated revenues exceeding CNY 40 billion, employed over 14,000 people worldwide, and distributed products to more than 190 countries and regions. The company allocates over 10% of revenue to R&D and holds more than 5,000 patents. Mindray continues its trajectory toward becoming a world-class enterprise.

Huitai Medical Devices Co., Ltd., established in 2002, listed on the Shanghai Stock Exchange STAR Market in January 2021. Built on proprietary R&D capabilities, Huitai is the only domestic Chinese manufacturer with the capacity to develop and produce electrophysiology electrode catheters and obtain regulatory approval. It ranks among the few Chinese firms capable of competing directly with international players. In 2023, Huitai reported revenues of CNY 1.65 billion; by 2024, its workforce had grown to 2,555 employees and total assets reached CNY 2.981 billion. In early 2024, Mindray acquired Huitai for CNY 6.65 billion in cash, providing immediate entry into the cardiovascular device market. Mindray intends to leverage its industry expertise and talent base to strengthen Huitai's R&D capabilities and enhance product performance.

3. Valuation Analysis of Huitai Medical Using the Discounted Cash Flow Model

Mindray Medical's competitive advantage stems from sustained technological innovation. With over 20% of employees in R&D, the company has developed proprietary technologies in medical imaging and in-vitro diagnostics that meet international standards and penetrate high-end markets in Europe and North America. Mindray also benefits from strong domestic market positioning and a global strategy targeting developing countries, leveraging inelastic demand driven by China's aging demographics. Nevertheless, the company faces headwinds from evolving healthcare reforms, procurement disruptions related to equipment modernization programs, and intensifying competition. As competitive pressures mount both domestically and internationally, the acquisition of Huitai Medical may represent a strategic inflection point, enabling Mindray to enter the cardiovascular device market and accelerate growth.

Valuation analysis constitutes the most critical component of mergers and acquisitions. Drawing on Huitai Medical's financial data from its 2023 and 2024 annual reports, we construct an absolute valuation model. The DCF methodology is selected because Huitai Medical has entered a stable profitability phase characterized by predictable and robust free cash flows to the firm (FCFF), aligning closely with the fundamental assumptions underlying DCF valuation. By estimating the company's future FCFF streams and discounting them to present value using an appropriate discount rate, we derive the firm's intrinsic value. Table 1 presents Huitai Medical's financial data for 2023 and 2024.

Table 1: Financial Data

	2023	2024
Operating Revenue (CNY 100 million)	16.5	20.66
Operating Revenue Growth Rate	35.71%	25.18%

Net Income (CNY 100 million)	5.34	6.73
Net Income Growth Rate	49.13%	26.08%
Net Profit Margin	32.36%	32.57%
Diluted Net Profit Return on Equity	28.00%	26.75%
Return on Total Assets	21.76%	23.70%
Total Asset-Liability Ratio	23.75%	14.29%
Earnings Per Share (CNY)	5.54	6.96
Net Assets Per Share (CNY)	28.52	25.84
Total Share Capital (100 million shares)	0.964	0.967

Data source: Xueqiu Finance (Xueqiu, 2025)

The valuation process begins with forecasting future Free Cash Flow to the Firm (FCFF). The discount rate is then determined using the Weighted Average Cost of Capital (WACC). Subsequently, the terminal value is computed, and all projected cash flows are discounted to present value to derive the enterprise value. The enterprise value is adjusted by subtracting net debt and adding non-operating assets to obtain the equity value, which is then divided by total shares outstanding to yield the intrinsic value per share.

Revenue growth constitutes the primary driver of the valuation model. Given Huitai Medical's robust growth rates exceeding 35% in 2023 and 25% in 2024—attributable to domestic substitution, product portfolio expansion, and market penetration—the company is expected to sustain above-industry growth in the near term. However, as the revenue base expands and competitive pressures intensify, the growth rate is projected to gradually decelerate and converge toward the long-term GDP growth rate (terminal growth rate). Table 2 presents the projected free cash flow estimates.

Table 2: Free Cash Flow Projections

Reporting Period / Forecast Period	2023A	2024A	2025E	2026E	2027E	2028E	2029E	2030+
Revenue (CNY billion)	16.5	20.66	25.21	29.75	34.21	38.32	42.15	44.26
Growth Rate	35.70%	25.20%	22.00%	18.00%	15.00%	12.00%	10.00%	5.00 %
Net Profit Margin	32.36%	32.57%	32.0%	32.0%	32.0%	32.0%	32.0%	32.0 %
Net Income (CNY billion)	5.34	6.73	8.07	9.52	10.95	12.26	13.49	14.16
Add: Depreciation and Amortization	1.00	1.20	1.40	1.65	1.90	2.15	2.40	2.52
Less: Increase in Working Capital	0.70	0.80	1.00	1.20	1.40	1.60	1.80	0.95
Less: Capital Expenditures (CAPEX)	1.20	1.50	1.80	2.10	2.40	2.70	3.00	3.15
= Free Cash Flow to the Firm (FCFF)	4.44	5.63	6.67	7.87	9.05	10.11	11.09	12.58

The company has maintained a stable historical net profit margin of approximately 32 %, demonstrating exceptional cost control and profitability. It is assumed that this high net profit margin will be sustained in the future. Free Cash Flow to the Firm (FCFF) is derived from net income, adjusted for non-cash expenses (depreciation and amortization), changes in working capital, and capital expenditures. Projections for these components were made based on historical asset turnover ratios and capital expenditure ratios.

The discount rate, which reflects investment risk, is another critical parameter. The Weighted Average Cost of Capital (WACC) model is employed for its calculation. The risk-free rate (Rf) is based on the yield of 10-year Chinese government bonds. The market risk premium (Rm - Rf) is set at an industry-standard 5.5 %. The beta (β) is selected as 1.10, the average for the medical device industry, reflecting the company's volatility relative to the market. The cost of debt (Rd) is assumed to be 4.0 %, given the company's low debt-to-equity ratio of 14.29 %, which implies minimal financing costs. The effective tax rate (T) is set at 15 %, accounting for tax incentives available to high-tech enterprises.

The cost of equity $(Re) = Rf + \beta * (Rm - Rf) = 3.0\% + 1.10 * 5.5\% = 9.05\% WACC = (E/V) * Re + (D/V) * Rd * (1 - T) = 85.71\% * 9.05\% + 14.29\% * 4.0\% * (1 - 15\%) \approx 8.21\%$

The forecasted Free Cash Flow to the Firm (FCFF) is discounted using the Weighted Average Cost of Capital (WACC) as the discount rate. The terminal value for the perpetual growth period is calculated using

the Gordon Growth Model, and the sum of these discounted cash flows yields the enterprise value. Table 3 presents an illustrative overview of the discounted free cash flow process.

$$(EV) = \sum[FCFFt/(1 + WACC)^t] + [FCFFn * (1 + g)/(WACC - g)]/(1 + WACC)^n$$

Table 3: Overview of Free Cash Flow to the Firm (FCFF) Discounting Process

Year	2025E	2026E	2027E	2028E	2029E	Perpetuity period
Free Cash Flow to the Firm (FCFF,CNY billion)	6.67	7.87	9.05	10.11	11.09	12.58
Discount Factor	0.92	0.85	0.79	0.73%	0.67%	0.67%
Present Value (CNY billion)	6.16%	6.72%	7.14	7.37	7.47	254.32
Enterprise Value (EV)				289.18		

Equity Value = Enterprise Value − Net Debt = 289.18 − (−10.2) = 299.38 (CNY billion, total equity) = 0.967 billion shares (outstanding) → Intrinsic value per share = 299.38 / 0.967 ≈ 309.55 CNY/share

Due to the inherent subjectivity in forecasting the growth rate (g) and discount rate (WACC), sensitivity analysis is conducted to demonstrate the valuation range across different assumptions. This approach offers superior analytical value compared to a single-point estimate. Table 4 displays the DCF valuation sensitivity analysis.

Table 4: Sensitivity Analysis Table for DCF Valuation

WACC\g	4.00%	4.50%	5.00%	5.50%
7.50%	345.2	368.5	398.2	437.1
8.00%	312.5	330.8	352.6	379.2
8.50%	285.2	299.8	316.8	337
9.00%	262.1	273.8	287.5	303.8
9.50%	242.30%	251.80%	262.9	275.9

In summary, based on the DCF intrinsic valuation model, the estimated value range for Huitai Medical is approximately CNY 262 to CNY 361, with a central value of around CNY 310. Regarding the reasonableness of the acquisition premium for Huitai Medical, the transaction price appears justifiable within market conditions. Premiums are a common phenomenon in mergers and acquisitions; however, as evidenced in the medical sector, the high-premium acquisition of M Pharmaceuticals by X Pharmaceutical Co., Ltd. yielded unfavorable outcomes, suggesting the potential for irrational premiums (Mo, 2018). Nevertheless, Mindray Medical's premium rate of 25% remains within a reasonable range for the broader medical market. Moreover, the acquisition benefits from significant synergistic effects, as Huitai Medical expands Mindray's market coverage and presence in the medical device sector. This premium reflects Mindray's high expectations and strategic emphasis on Huitai, while the acquisition price is comfortably manageable given Mindray's cash reserves, avoiding equity dilution or excessive debt burdens. Consequently, this premium is appears reasonable, and Mindray stands to gain substantially from the transaction. The future success of Mindray's market share and strategic positioning in the medical sector appears promising at present. The acquisition of Huitai Medical effectively fills critical gaps in Mindray's portfolio; however, as both are domestic brands facing dominant foreign competitors such as Johnson & Johnson and Abbott in the electrophysiological market, significant challenges remain. The ultimate success of this acquisition will depend on Mindray's ability to sustain growth and successfully integrate Huitai Medical in the future.

4. Conclusion

This study evaluate Mindray Medical's 2024 acquisition of Huitai Medical for CNY 6.65 billion, focusing on the valuation methodology and the reasonableness of the pricing. It commences with an overview of both companies: Mindray Medical, a leading domestic provider of comprehensive medical devices, recorded revenues exceeding CNY 40 billion in 2023, with distinctive strengths in technological innovation, market positioning, and global expansion; it allocates over 20% of its workforce to research and development and distributes products in more than 190 countries and regions. Huitai Medical, a prominent player in the electrophysiological sector with strong core competitiveness, is among the few domestic firms capable of rivaling international peers; it reported revenues of CNY 1.65 billion in 2023 and expanded total assets to CNY 2.981 billion by 2024, demonstrating robust growth momentum.

Drawing on Huitai Medical's financial data for 2023–2024, the analysis applies a Discounted Cash Flow (DCF) model to estimate value, projecting revenues, net income, and Free Cash Flow to the Firm (FCFF) from 2025 to 2030 and into perpetuity. Employing a Weighted Average Cost of Capital (WACC) of 8.21% as the discount rate and a terminal growth model, the enterprise value is calculated at CNY 28.918 billion, equity value at CNY 29.938 billion, and intrinsic per-share value at approximately CNY 309.55. Sensitivity analysis yields an intrinsic value range of CNY 262–361 per share. The analysis concludes that the 25% acquisition premium is justifiable within the medical device sector's norms, underpinned by substantial synergies between Mindray and Huitai, alongside Mindray's limited financial strain.

For Mindray Medical's post-acquisition strategy, integration with Huitai Medical should be prioritized, harnessing Mindray's advantages in technology, talent, and distribution channels to bolster Huitai's R&D capabilities and product performance. This approach would enlarge their joint market share in cardiovascular and electrophysiological segments, enabling stronger competition against global leaders such as Johnson & Johnson and Abbott. Deeper collaboration in product innovation and market penetration holds promise for reciprocal gains.

Nevertheless, this study is subject to several limitations. First, the DCF model is contingent upon several critical assumptions; any material deviations, including slower-than-expected domestic import substitution, more stringent accounts receivable management, or setbacks in new product commercialization, could substantially reduce projected growth. Second, the valuation framework does not incorporate exogenous shocks such as macroeconomic instability or changes in market sentiment, which may compromise the precision of our estimates.

References

Cao, W., (2015). *Valuation analysis of real options in corporate mergers and acquisitions.* Master's Thesis, Shanghai Jiao Tong University.

Mo, D. Q., (2018). *Analysis of the Premium and Result of Medical Merger and Acquisition: In Case of X Company Merge M Company.* Master's Thesis, Guangdong University of Foreign Studies.

Ren, Y., (2020). *Research on M & A valuation risk management of intelligent rail transit enterprises based on multiple method: Taking bll trans tech merges and acquires huaqi intelligent as an example.* Master's Thesis, Beijing Jiaotong University.

Xueqiu, (2025). *Key financial indicators of Huitai Medical (SH688617)* [Online]. Available: https://xueqiu.com/snowman/S/SH688617/detail#/ZYCWZB [Accessed 10 December 2025].

Yang, L., (2023). *The impact of mergers and acquisitions in the food and beverage industry on company valuation.* Master's Thesis, Donghua University.

Yang, Z. K., (2015). Valuation analysis in power company mergers and acquisitions: A case study of huineng power's acquisition of kebian electric. *Times Finance***,** no. 15, pp. 17-18.

Zhang, Y. T., (2021). *Valuation analysis of target company of Alibaba's acquisition of youkutudou.* Master's Thesis, Harbin University of Commerce.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgment

This paper is an output of the science project.